Influence of the Concomitant Use of Clopidogrel and Proton Pump Inhibitors on Adverse Cardiovascular Events in Korean Patients with Acute Coronary Syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Recent investigations suggest that the antiplatelet effect of clopidogrel may be decreased when thismedication is taken together with certain proton pump inhibitors (PPIs). However, there has been no studyconducted in Korea regarding the clinical effect of clopidogrel-PPI interaction. This study targeted patientswho received stents to investigate the effect of the concomitant use of clopidogrel and PPIs on the occurrenceof adverse cardiovascular events in Korean patients. Methods: The patients who received a stentinsertion at the Yeouido St. Mary’s Hospital between January 2010 and April 2011 were included. Thepatients were divided into two groups, clopidogrel and clopidogrel + PPI, and followed for 12 months afterthe date of stent insertion using prescription history and medical records. The recurrence rates of the cardiovascularevents among the two patient groups were statistically analyzed. Results: There was no differencebetween the two groups in the basic characteristics of the 157 patients in the clopidogrel group andthe 62 patients in the clopidogrel + PPI group. Simple logistic regression showed a significantly higher rateof re-hospitalization in the clopidogrel + PPI group (OR=1.893, 95% CI 1.040-3.445, p=0.037). However, theresults of the multivariate logistic regression of the variables found to have statistical significance bycrosstabulation showed no significant difference in the rate of adverse cardiovascular events or re-hospitalizationbetween the two groups. Conclusions: There was no significant difference between the clopidogrel andclopidogrel+PPI group among new patients with cardiovascular stents with respect to the occurrence ofrevascularization procedures, stent thrombosis, or chest pain, or with respect to the re-hospitalization rate forall cardiovascular events.
Abstract
Purpose: Recent investigations suggest that the antiplatelet effect of clopidogrel may be decreased when thismedication is taken together with certain proton pump inhibitors (PPIs). However, there has been no studyconducted in Korea regarding the clinical effect of clopidogrel-PPI interaction. This study targeted patientswho received stents to investigate the effect of the concomitant use of clopidogrel and PPIs on the occurrenceof adverse cardiovascular events in Korean patients. Methods: The patients who received a stentinsertion at the Yeouido St. Mary’s Hospital between January 2010 and April 2011 were included. Thepatients were divided into two groups, clopidogrel and clopidogrel + PPI, and followed for 12 months afterthe date of stent insertion using prescription history and medical records. The recurrence rates of the cardiovascularevents among the two patient groups were statistically analyzed. Results: There was no differencebetween the two groups in the basic characteristics of the 157 patients in the clopidogrel group andthe 62 patients in the clopidogrel + PPI group. Simple logistic regression showed a significantly higher rateof re-hospitalization in the clopidogrel + PPI group (OR=1.893, 95% CI 1.040-3.445, p=0.037). However, theresults of the multivariate logistic regression of the variables found to have statistical significance bycrosstabulation showed no significant difference in the rate of adverse cardiovascular events or re-hospitalizationbetween the two groups. Conclusions: There was no significant difference between the clopidogrel andclopidogrel+PPI group among new patients with cardiovascular stents with respect to the occurrence ofrevascularization procedures, stent thrombosis, or chest pain, or with respect to the re-hospitalization rate forall cardiovascular events.
참고문헌 (31)
- Roger VL., "Heart disease and stroke statistics--2012 update : a report from the American Heart Association", Circulation, 125, pp.e2~e220 (2012)
- Schampaert E., "The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries(C-SIRIUS)", J Am Coll Cardiol, 43, pp.1110~1115 (2004)
- Park SJ., "Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis : comparison with bare metal stent implantation", J Am Coll Cardiol, 45, pp.351~356 (2005)
- Appleby CE., "Late outcomes following percutaneous coronary interventions : results from a large, observational registry", Can J Cardiol, 26, pp.e218~e224 (2010)
- Kushner FG., "2009 Focused Updates : ACC", AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction(updating the 2004 Guideline and 2007 Focused Update)and ACC, SCAI Guidelines on Percutaneous Coronary Intervention(updating the 2005 Guideline and 2007 Focused Update) : a report of the American College of Cardiology Foundation, pp.American Heart Association Task Force on Practice Guidelines, Circulation[DOI]
- Yu T., "Biocontrol of blue and gray mold diseases of pear fruit by integration of antagonistic yeast with salicylic acid", Int J Food Microbiol, 116, pp.339~345 (2007)
- Stauffer JC., "Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus", Swiss Med Wkly, 142, pp.w13573~ (2012)
- Gilard M., "Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin", J Thromb Haemost, 4, pp.2508~2509 (2006)
- Lau WC., "Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation : a new drug-drug interaction", Circulation, 107, pp.32~37 (2003)
- Fontana P., "Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects", Circulation, 108, pp.989~995 (2003)
- Hulot JS., "Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects", Blood, 108, pp.2244~2247 (2006)
- Ishizaki T., "Review article : cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole", Aliment Pharmacol Ther, 13(Suppl 3), pp.27~36 (1999)
- Ho PM., "Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome", JAMA, 301, pp.937~944 (2009)
- Gilard M., "Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin : the randomized, double-blind OCLA(Omeprazole CLopidogrel Aspirin)study", J Am Coll Cardiol, 51, pp.256~260 (2008)
- Jeremias A., "Stent thrombosis after successful sirolimus-eluting stent implantation", Circulation, 109, pp.1930~1932 (2004)
- Iakovou I., "Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents", JAMA, 293, pp.2126~2130 (2005)
- Artang R., "Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries", Am J Cardiol, 99, pp.1039~1043 (2007)
- Grines CL., "Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents : a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians", Catheter Cardiovasc Interv, 69, pp.334~340 (2007)
- Abraham NS., "ACCF", ACG, ACG, pp.AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use : a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents, Circulation[DOI]
- Hulot JS., "Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration : a systematic meta-analysis", J Am Coll Cardiol, 56, pp.134~143 (2010)
- Siller-Matula JM., "Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel : a systematic review and metaanalysis", J Thromb Haemost, 8, pp.2624~2641 (2010)
- Juurlink DN., "A population-based study of the drug interaction between proton pump inhibitors and clopidogrel", CMAJ, 180, pp.713~718 (2009)
- Rassen JA., "Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome", Circulation, 120, pp.2322~2329 (2009)
- Stockl KM., "Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor", Arch Intern Med, 170, pp.704~710 (2010)
- van Boxel OS., "Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study", Am J Gastroenterol, 105, pp.2430~2436 (2010)
- Schmidt M., "Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation", Aliment Pharmacol Ther, 35, pp.165~174 (2012)
- Yasu T., "Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation : a retrospective cohort study", Yakugaku Zasshi, 130, pp.1743~1750 (2010)
- Zuern CS., "Effect of comedication with proton pump inhibitors(PPIs)on postinterventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy", Thromb Res, 125, pp.e51~e54 (2010)
- Cuisset T., "Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA(Proton Pump Inhibitors And Clopidogrel Association)prospective randomized study", J Am Coll Cardiol, 54, pp.1149~1153 (2009)
- Sibbing D., "Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel", Thromb Haemost, 101, pp.714~719 (2009)
- Kreutz RP., "Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement : the clopidogrel Medco outcomes study", Pharmacotherapy, 30, pp.787~796 (2010)